Cytokeratin immunostaining patterns of benign, reactive lymph nodes: Applications for the evaluation of sentinel lymph node specimen

Citation
Md. Linden et Rj. Zarbo, Cytokeratin immunostaining patterns of benign, reactive lymph nodes: Applications for the evaluation of sentinel lymph node specimen, APPL IMMUNO, 9(4), 2001, pp. 297-301
Citations number
27
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
ISSN journal
10623345 → ACNP
Volume
9
Issue
4
Year of publication
2001
Pages
297 - 301
Database
ISI
SICI code
1062-3345(200112)9:4<297:CIPOBR>2.0.ZU;2-U
Abstract
The use and interpretation of cytokeratin (CK) immunostains of sentinel lym ph node specimens for breast carcinoma remain controversial. Variable immun oreactivity with anti-CK antibodies and CK-positive interstitial reticulum cells may complicate interpretation. The authors examined a series of react ive lymph nodes selected from patients without a history of malignancy. To demonstrate potential diagnostic pitfalls, three different CK antibody comb inations were studied to characterize the immunostaining patterns. Formalin -fixed sections of lymph nodes were immunostained with a labeled streptavid in-biotin method using a DAKO autostainer. The anti-CK antibody preparation s evaluated were AE1/AE3, CAM 5.2, and an inhouse-prepared CK cocktail comp osed of 7 antibodies. The authors observed that up to 10% of cells in benig n, reactive lymph nodes may be immunoreactive with anti-CK antibodies. AE1/ AE3 stained 2 of 20 cases with rare immunoreactive reticulum cells, whereas CAM 5.2 and the CK cocktail immunostained cells in 85% of cases with retic ulum cells in sinuses and the paracortex. Rare positive to 2+ cells were pr esent in a similar distribution with these two antibodies. Careful interpre tation of CK immunostaining of sentinel lymph node biopsies is essential, a s is awareness of the presence of CK-positive native reticulum. cells, to a void confusion with single cells of metastatic carcinoma.